• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Wall Street's Most Accurate Analysts Say Buy These 3 Health Care Stocks With Over 3% Dividend Yields

    7/15/24 2:08:21 PM ET
    $CVS
    $MDT
    $PFE
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $CVS alert in real time by email

    During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

    Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.

    Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.

    Pfizer Inc. (NYSE:PFE)

    • Dividend Yield: 5.81%
    • Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating with a price target of $45 on July 10. This analyst has an accuracy rate of 70%.
    • BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and raised the price target from $33 to $36 on May 2. This analyst has an accuracy rate of 70%.
    • Recent News: On July 11, Pfizer announced it selected its preferred once-daily modified release formulation for danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist.
    • Benzinga Pro's real-time newsfeed alerted to latest Pfizer's news

    CVS Health Corporation (NYSE:CVS)

    • Dividend Yield: 4.51%
    • Argus Research analyst Chris Graja maintained a Buy rating and cut the price target from $100 to $80 on May 8. This analyst has an accuracy rate of 70%.
    • Truist Securities analyst David Macdonald reiterated a Buy rating and lowered the price target from $90 to $66 on May 2. This analyst has an accuracy rate of 71%.
    • Recent News: CVS Health said it will report second-quarter financial results on Wednesday, Aug. 7.
    • Benzinga Pro's charting tool helped identify the trend in CVS stock.

    Medtronic plc (NYSE:MDT)

    • Dividend Yield: 3.59%
    • Wells Fargo analyst Larry Biegelsen maintained an Overweight rating and raised the price target from $102 to $105 on May 24. This analyst has an accuracy rate of 73%.
    • Mizuho analyst Anthony Petrone maintained a Buy rating and increased the price target from $95 to $98 on Feb. 21. This analyst has an accuracy rate of 65%.
    • Recent News: On June 26, Medtronic announced the resignation of EVP and CFO Karen Parkhill.
    • Benzinga Pro's signals feature notified of a potential breakout in Medtronic's shares.

    Read More:

    • How To Earn $500 A Month From Bank of America Stock Ahead Of Q2 Earnings
    Get the next $CVS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CVS
    $MDT
    $PFE

    CompanyDatePrice TargetRatingAnalyst
    CVS Health Corporation
    $CVS
    3/12/2026$94.00Mkt Perform → Outperform
    Bernstein
    Pfizer Inc.
    $PFE
    3/2/2026$35.00Hold → Buy
    Argus
    Pfizer Inc.
    $PFE
    2/25/2026$25.00Underperform
    RBC Capital Mkts
    Pfizer Inc.
    $PFE
    2/20/2026$25.00Underweight
    Barclays
    Medtronic plc.
    $MDT
    2/13/2026$116.00Overweight
    Barclays
    Pfizer Inc.
    $PFE
    2/12/2026$27.00Outperform → Neutral
    Daiwa Securities
    Medtronic plc.
    $MDT
    2/9/2026$121.00Hold → Buy
    Needham
    Medtronic plc.
    $MDT
    2/3/2026$117.00Buy
    Citigroup
    More analyst ratings

    $CVS
    $MDT
    $PFE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Hancock Dennis P

    3 - PFIZER INC (0000078003) (Issuer)

    4/10/26 1:10:35 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Shah Prem S

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    4/2/26 4:58:11 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 4 filed by Newman Brian

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    4/2/26 4:57:02 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    $MDT
    $PFE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Medtronic to announce financial results for its fourth quarter and full fiscal year 2026

    GALWAY, Ireland, April 13, 2026 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results on Wednesday, June 3, 2026, for its fourth quarter and full fiscal year 2026, which ends on Friday, April 24, 2026.A news release containing summary financial information will be issued at 5:45 a.m. Central Time (CT) and will be available at https://news.medtronic.comA video webcast to discuss results will begin at 6:45 a.m. CT and can be accessed at https://investorrelations.medtronic.comWithin 24 hours of the video webcast, a replay and transcript of the prepared remarks will be available by clicking on the Events link at

    4/13/26 6:00:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders

    Pfizer Inc. (NYSE:PFE) announced today that its shareholders and the general public are invited to access its virtual 2026 Annual Meeting of Shareholders on Thursday, April 23, 2026, at 9:00 a.m. EDT. Shareholders can find information on accessing and registering for the virtual meeting at https://meetnow.global/PFE2026. On the day of the Annual Meeting, shareholders may begin logging into the virtual meeting platform at 8:45 a.m. EDT using either the control number found on their proxy card, voting instruction form or the notice that was previously received. Only shareholders who log into the meeting using a control number will have the ability to ask questions or vote during the live me

    4/9/26 10:00:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Telix Strengthens Board with Additional Director Appointments

    MELBOURNE, Australia and INDIANAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces two additional Non-Executive Director (NED) appointments, effective May 11, 20261, as part of Board expansion and succession planning: Maria Rivas, MD is an experienced public company board director and S&P 100 senior pharmaceutical executive with more than 25 years' experience in late-stage clinical development, commercialization and governance leadership. Dr. Rivas currently serves on the board of directors of The Cooper Companies, Inc. (NASDAQ:COO), a medical technology company, and also served as an independent director for Medidata

    4/8/26 6:44:20 PM ET
    $ANIK
    $AVNT
    $COO
    Medical/Dental Instruments
    Health Care
    Major Chemicals
    Industrials

    $CVS
    $MDT
    $PFE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    10/25/24 2:48:21 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for HYMPAVZI issued to PFIZER INC

    Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

    10/15/24 2:57:27 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

    For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

    10/11/24 2:12:15 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CVS
    $MDT
    $PFE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CVS Health upgraded by Bernstein with a new price target

    Bernstein upgraded CVS Health from Mkt Perform to Outperform and set a new price target of $94.00

    3/12/26 8:38:26 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Pfizer upgraded by Argus with a new price target

    Argus upgraded Pfizer from Hold to Buy and set a new price target of $35.00

    3/2/26 8:00:47 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on Pfizer with a new price target

    RBC Capital Mkts initiated coverage of Pfizer with a rating of Underperform and set a new price target of $25.00

    2/25/26 7:53:28 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CVS
    $MDT
    $PFE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and President, Aetna Nelson Steven H bought $1,289 worth of shares (24 units at $53.70) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    1/27/26 5:20:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    EVP and Chief People Officer Capozzi Heidi B bought $4,589 worth of shares (80 units at $57.36) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    10/14/25 7:08:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Director Jellison William R bought $462,750 worth of Ordinary Shares (5,000 units at $92.55) (SEC Form 4)

    4 - Medtronic plc (0001613103) (Issuer)

    8/25/25 5:18:06 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CVS
    $MDT
    $PFE
    SEC Filings

    View All

    SEC Form DEF 14A filed by CVS Health Corporation

    DEF 14A - CVS HEALTH Corp (0000064803) (Filer)

    4/3/26 4:05:26 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form DEFA14A filed by CVS Health Corporation

    DEFA14A - CVS HEALTH Corp (0000064803) (Filer)

    4/3/26 4:05:57 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Amendment: SEC Form SCHEDULE 13G/A filed by Medtronic plc.

    SCHEDULE 13G/A - Medtronic plc (0001613103) (Subject)

    3/27/26 10:30:11 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CVS
    $MDT
    $PFE
    Financials

    Live finance-specific insights

    View All

    CVS Health to hold first quarter 2026 earnings conference call

    WOONSOCKET, R.I., April 6, 2026 /PRNewswire/ -- CVS Health® (NYSE:CVS) will hold a conference call with analysts and investors on Wednesday, May 6th, 2026, at 8:00 a.m. ET to discuss first quarter 2026 financial results. An audio webcast of the event will be broadcast simultaneously on the Investor Relations portion of the CVS Health website at investors.cvshealth.com where it will be archived for a period of one year.About CVS HealthCVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of December 31, 2025, the

    4/6/26 9:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts

    Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, May 5, 2026. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's First Quarter 2026 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to register in advance of the conference call. You can also listen to the conference

    3/24/26 10:00:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CVS Health declares quarterly dividend

    WOONSOCKET, R.I., March 18, 2026 /PRNewswire/ -- CVS Health® (NYSE: CVS) has announced that its board of directors has approved a quarterly dividend of sixty-six and one-half cents ($0.665 cents) per share on the Common Stock of the Corporation. The dividend is payable on May 4, 2026, to holders of record on April 23, 2026. About CVS HealthCVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of December 31, 2025, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary c

    3/18/26 5:15:00 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    $MDT
    $PFE
    Leadership Updates

    Live Leadership Updates

    View All

    ParaZero Strengthens Global Sales Leadership with Appointment of Bat-Sheva Noy as VP

    Kfar Saba, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (NASDAQ:PRZO) (the "company" or "ParaZero"), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, recently announced the appointment of Bat-Sheva Noy as its new Vice President of Global Sales. Ms. Noy brings more than 20 years of extensive commercial and leadership experience, with particular expertise in strategic planning, market access, and leading cross-functional teams. Most recently, from 2020 to 2025, she served as the Business Unit Lead for Rare Diseases at Pfizer Israel ((a subsidiary of Pfizer Inc., NYSE:PFE). In that

    3/4/26 8:32:00 AM ET
    $PFE
    $PRZO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Military/Government/Technical
    Industrials

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    CVS Health Helps Improve Access to More Affordable Fertility Treatments

    WOONSOCKET, R.I., Oct. 16, 2025 /PRNewswire/ -- CVS Health (NYSE:CVS) today announced it will support simpler access to more affordable fertility treatments for all Americans through its CVS Specialty Pharmacy and make it easier to pick up fertility medication at its 9,000 community pharmacy locations. CVS Specialty Pharmacy will be a core partner in the TrumpRx Fertility program. As the Trump Administration continues to establish more competitive prices for important medicines, the Administration has engaged with EMD Serono, manufacturer of Gonal-F an in-vitro fertilization (

    10/16/25 5:09:00 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    $MDT
    $PFE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CVS Health Corporation

    SC 13G - CVS HEALTH Corp (0000064803) (Subject)

    11/13/24 1:00:57 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

    SC 13G/A - Medtronic plc (0001613103) (Subject)

    2/13/24 5:09:43 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by CVS Health Corporation (Amendment)

    SC 13G/A - CVS HEALTH Corp (0000064803) (Subject)

    2/13/24 5:02:40 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples